Cardiovascular Imaging and Theranostics in Cardiovascular Pharmacotherapy

Imaging plays a pivotal role in the diagnostic and prognostic assessment of cardiovascular diseases. During the past two decades, there has been an expansion of the available imaging techniques, some of which are now part of routine clinical practice. Cardiovascular imaging of atherosclerosis is a u...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mattia Cattaneo, Alberto Froio, Augusto Gallino
Formato:	article
Lenguaje:	EN
Publicado:	Radcliffe Medical Media 2019
Materias:	Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/05ae3bd5e640416c8fbc9c9c1e3ada32
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:05ae3bd5e640416c8fbc9c9c1e3ada32
record_format	dspace
spelling	oai:doaj.org-article:05ae3bd5e640416c8fbc9c9c1e3ada322021-12-04T16:01:23ZCardiovascular Imaging and Theranostics in Cardiovascular Pharmacotherapy10.15420/ecr.2019.6.11758-37641758-3756https://doaj.org/article/05ae3bd5e640416c8fbc9c9c1e3ada322019-01-01T00:00:00Zhttps://www.ecrjournal.com/articles/cardiovascular-imaging-and-theranostics-cardiovascular-pharmacotherapyhttps://doaj.org/toc/1758-3756https://doaj.org/toc/1758-3764Imaging plays a pivotal role in the diagnostic and prognostic assessment of cardiovascular diseases. During the past two decades, there has been an expansion of the available imaging techniques, some of which are now part of routine clinical practice. Cardiovascular imaging of atherosclerosis is a useful instrument, and it can corroborate and expand pathophysiological evidence on cardiovascular disease, providing proof of concept for medical therapy and can predict its responsiveness, and it may be able to be used as surrogate endpoints for clinical trials. Theranostics is an emerging therapy that combines imaging and therapeutic functions, using imaging-based therapeutic delivery systems. Theranostics could partially overcome current imaging limitations and translate experimental evidence and large-scale trials assessing clinical endpoints, rationalising cardiovascular drug development and paving the way to personalised medicine. The medical community cannot overlook the use of cardiovascular imaging as a complementary and supportive adjunct to trials investigating clinical endpoints, which remain the mainstay for investigating the efficacy and safety of cardiovascular pharmacotherapy.Mattia CattaneoAlberto FroioAugusto GallinoRadcliffe Medical MediaarticleDiseases of the circulatory (Cardiovascular) systemRC666-701ENEuropean Cardiology Review , Vol 14, Iss 1, Pp 62-64 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the circulatory (Cardiovascular) system RC666-701
spellingShingle	Diseases of the circulatory (Cardiovascular) system RC666-701 Mattia Cattaneo Alberto Froio Augusto Gallino Cardiovascular Imaging and Theranostics in Cardiovascular Pharmacotherapy
description	Imaging plays a pivotal role in the diagnostic and prognostic assessment of cardiovascular diseases. During the past two decades, there has been an expansion of the available imaging techniques, some of which are now part of routine clinical practice. Cardiovascular imaging of atherosclerosis is a useful instrument, and it can corroborate and expand pathophysiological evidence on cardiovascular disease, providing proof of concept for medical therapy and can predict its responsiveness, and it may be able to be used as surrogate endpoints for clinical trials. Theranostics is an emerging therapy that combines imaging and therapeutic functions, using imaging-based therapeutic delivery systems. Theranostics could partially overcome current imaging limitations and translate experimental evidence and large-scale trials assessing clinical endpoints, rationalising cardiovascular drug development and paving the way to personalised medicine. The medical community cannot overlook the use of cardiovascular imaging as a complementary and supportive adjunct to trials investigating clinical endpoints, which remain the mainstay for investigating the efficacy and safety of cardiovascular pharmacotherapy.
format	article
author	Mattia Cattaneo Alberto Froio Augusto Gallino
author_facet	Mattia Cattaneo Alberto Froio Augusto Gallino
author_sort	Mattia Cattaneo
title	Cardiovascular Imaging and Theranostics in Cardiovascular Pharmacotherapy
title_short	Cardiovascular Imaging and Theranostics in Cardiovascular Pharmacotherapy
title_full	Cardiovascular Imaging and Theranostics in Cardiovascular Pharmacotherapy
title_fullStr	Cardiovascular Imaging and Theranostics in Cardiovascular Pharmacotherapy
title_full_unstemmed	Cardiovascular Imaging and Theranostics in Cardiovascular Pharmacotherapy
title_sort	cardiovascular imaging and theranostics in cardiovascular pharmacotherapy
publisher	Radcliffe Medical Media
publishDate	2019
url	https://doaj.org/article/05ae3bd5e640416c8fbc9c9c1e3ada32
work_keys_str_mv	AT mattiacattaneo cardiovascularimagingandtheranosticsincardiovascularpharmacotherapy AT albertofroio cardiovascularimagingandtheranosticsincardiovascularpharmacotherapy AT augustogallino cardiovascularimagingandtheranosticsincardiovascularpharmacotherapy
_version_	1718372773547474944

Cardiovascular Imaging and Theranostics in Cardiovascular Pharmacotherapy

Ejemplares similares